BMS-986213 (Relatlimab-Nivolumab FDC) Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since August 2026

Also known as: BMS-986016, Relatlimab

Pipeline

Phase 2: 1

Top Sponsors

M.D. Anderson Cancer Center1

Indications

Melanoma (Skin)1
Cancer1

Houston, Texas1 trial

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.